Companies Dominating the Non-alcoholic Steatohepatitis Treatment Landscape
- Intercept Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer, Inc.
- Inventiva
- Galmed Pharmaceuticals Ltd.
- Novo Nordisk A/S
- Madrigal Pharmaceuticals
- Galectin Therapeutics
- NGM Biopharmaceuticals
- Brsitol-Myers Squibb Company
- Can Fite
- Zydus Lifesciences Ltd.
- Mitsubishi Chemical Group Corporation
Browse Key Market Insights with Data Illustration:
In the News
- Novo Nordisk A/S announced the extension of their collaboration with Gilead Sciences, Inc. for clinical trials in non-alcoholic steatohepatitis (NASH). The companies plans to carry out a phase 2b double-blind, placebo-controlled study to examine the safety and effectiveness of semaglutide, a GLP-1 receptor agonist from Novo Nordisk, and a fixed-dose combination of cilofexor, an investigational FXR agonist, and firsocostat, an investigational ACC inhibitor.
- Pfizer, Inc. announces the fast track designation grant from U.S. Food and Drug Administration (FDA) to company’s investigational combination medication for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. This will speed up the review process and make it easier to create new medications and vaccines that are meant to treat or prevent serious illnesses and meet unmet medical needs.
